Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 10/20 | 0.37 |
| ▸ | SLC16A1 | P53985 | 9/20 | 0.37 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699218 | 0.86 | SLC16A3 (0.36) | SLC16A3SLC16A1CNR1RXRANR1H2 | |
| SCHEMBL476365 | 0.86 | APLNR (0.35) | KCNA5 | |
| SCHEMBL3705663 | 0.84 | DPP4 (0.37) | NR1H3KCNA5KCNH2 | |
| SCHEMBL4125769 | 0.83 | SLC16A3 (0.39) | SLC16A3SLC16A1CNR1 | |
| SCHEMBL4126098 | 0.83 | NAMPT (0.39) | SLC16A3SLC16A1CNR1 | |
| Hydrochloric Acid SCHEMBL3693726 | 0.82 | RXRA (0.37) | CNR1RXRANR1H2NR1H3 | |
| SCHEMBL4139027 | 0.82 | CNR1 (0.39) | SLC16A3SLC16A1MCTS1CNR1 | |
| SCHEMBL3705041 | 0.82 | SLC16A3 (0.39) | SLC16A3SLC16A1CNR1 | |
| SCHEMBL3702449 | 0.81 | ALDH1A1 (0.44) | SLC16A3SLC16A1CNR1ALDH1A1 | |
| SCHEMBL4126819 | 0.80 | CNR1 (0.38) | SLC16A3SLC16A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2190822-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC16A3 2809/4885SLC16A1 2925/4885MCTS1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.